Navigation Links
Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)
Date:9/17/2013

e therapy in the first 6 hours after surgery, representing a substantial unmet medical need and commercial opportunity.

PONV offers Acacia Pharma a rapid development opportunity for APD421, owing to the acute nature of the condition, the large number of surgical procedures and the well-documented, benign safety profile of amisulpride, which has been widely used at much higher doses as an antipsychotic agent for 25 years. Amisulpride is also being developed by Acacia Pharma as APD403 for the prevention of chemotherapy induced nausea & vomiting (CINV).

Dr Gabriel Fox, Acacia Pharma's Chief Medical Officer commented: "Our Phase 3 programme will give a very robust read-out on the efficacy and safety of APD421 compared to placebo in a broad population of surgical patients at risk of suffering PONV. We have been highly encouraged by the positive feedback from regulatory agencies and experienced clinical investigators in Europe and the US and look forward to seeing the data from these studies."

Acacia Pharma's CEO, Dr Julian Gilbert, added: "We are delighted to have initiated these Phase 3 studies so soon after securing our recent funding. The Phase 2 data we generated last year were excellent and we are confident of obtaining similar results in these bigger pivotal clinical studies."

About Acacia Pharma

Acacia Pharma (http://www.acaciapharma.com) is a pharmaceutical company focused on cancer supportive care, a rapidly developing commercial opportunity. The growth in the cancer supportive care market has been driven by the increasing incidence of cancer, the expansion of effective cancer therapies and the desire to improve both the effectiveness of treatment and the quality of life of cancer patients.

Acacia Pharma has generated a pipeline of product opportunities addressing a range of supportive care i
'/>"/>

SOURCE Acacia Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care
2. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
3. AEgis Technologies Announces Official Launch of ADME WorkBench Software for Pharmacokinetics Prediction
4. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
5. Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
6. Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
7. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
8. Inovio Pharmaceuticals to Hold Investor Conference Call to Discuss Partnership with Roche
9. ViroPharma To Participate In The Stifel Nicolaus 2013 Healthcare Conference
10. PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
11. Bio/Pharmaceutical Contract Manufacturing - Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... observed the fractional quantum Hall effect in bilayer graphene ... be tuned by an electric field. , The ... confined to thin sheets are exposed to large magnetic ... thousands of individual electrons behave as a single system. ... well established, many details of this collective behavior remain ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
Breaking Biology Technology:Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Even geckos can lose their grip 2
... 2011 Vermillion, Inc. (NASDAQ: VRML ), a ... call to give a company update following issuance of the ... Conference Call Information To access ... United States and Canada or +1 303 223-2683 internationally.  The ...
... Calif., April 19, 2011 Life Technologies ... will present at Baird,s 2011 Growth Stock Conference on ... Technologies, Chairman and Chief Executive Officer, will present on ... presentation, which will be available for three weeks following ...
... Today, H. Shep Wild, President and Chief Executive ... company focused on the research and development of ... a company overview to venture capital, pharmaceutical and ... Showcase 2011 hosted by the University of Florida ...
Cached Biology Technology:Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011 2Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011 3Life Technologies to Present at Baird's 2011 Growth Stock Conference 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 3CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 4
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... 2014  Pomerantz LLP has filed a class ... the "Company")(NYSE-MKT: PVCT) and certain of its officers.  ... Court, Middle District of Tennessee ... class consisting of all persons or entities who ... 17, 2013 and May 22, 2014, both dates ...
(Date:7/10/2014)... -- Unisys Corporation,s (NYSE: UIS ) subsidiary in ... that it has been selected by the Dutch Custodial Institutions ... Provision Biometrics solution for penitentiaries across The Netherlands ... a solution based on its open standards-based LEIDA ... is up to seven years, with the new system expected ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... as a means to increase vegetation and preserve aesthetics ... cities, local character and biodiversity, researchers are looking to ... environments that are necessary in lightweight green roof design. ... survive in environments with little water--fit well in green ...
... fresh produce increases, vegetable and fruit producers are ... being challenged to examine traditional production practices in ... impact. A recent focus on both the positive ... across the globe working to find methods that ...
... 31 January 2014 VIB and CD3 (KU Leuven) ... agreement with AstraZeneca for the development of novel MALT1 ... The research teams of Thijs Baens and Peter ... Beyaert (VIB-UGent, Inflammation Research Center) were among the first ...
Cached Biology News:Three native aromatics indicated for use in Mediterranean extensive green roofs 2Nitrogen management studied in greenhouse pepper production 2VIB&CD3 enter into license and collaboration agreement with AstraZeneca for development of MALT1 inhibitor 2
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse TrkC Affinity Purified Polyclonal Ab...
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Biology Products: